STOCKS | Abivax Jumps as Much as 27% After Trial Update Eases Cancer Concerns
2026-06-30 07:55:59
Abivax SA shares surged as much as 27% after a clinical-trial update eased some investors’ concerns that cancer could be a potential side effect of the biotech’s most promising experimental drug, according to Bloomberg.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
特斯拉推送FSD v14 Lite股价涨超8%
